-+ 0.00%
-+ 0.00%
-+ 0.00%

China SXT Pharmaceuticals FY26 net loss widens to $6.21 million; revenue drops 35% to $1.14 million

PUBT·07/01/2026 20:32:36
Listen to the news
China SXT Pharmaceuticals FY26 net loss widens to $6.21 million; revenue drops 35% to $1.14 million
  • China SXT Pharmaceuticals fiscal 2026 net loss widened 88% to USD 6.21 million as revenue fell 35% to USD 1.14 million.
  • Operating loss widened 166% to USD 7.12 million, while gross profit slipped 32% to USD 248,702.
  • General and administrative expenses jumped 158% to USD 7.13 million, driven by USD 5.31 million of employee incentives.
  • Advanced TCMP revenue dropped 81% to USD 49,516, while Regular TCMP revenue declined 25% to USD 1.08 million.
  • Cash, cash equivalents and restricted cash rose to USD 28.18 million as net cash from financing activities increased to USD 14.43 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China SXT Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-074310), on July 01, 2026, and is solely responsible for the information contained therein.